ID   PWR-1E
AC   CVCL_3775
SY   PWR1E
DR   BTO; BTO:0005178
DR   CLO; CLO_0008671
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-11611
DR   BioSample; SAMN03471342
DR   cancercelllines; CVCL_3775
DR   Cell_Model_Passport; SIDM01114
DR   ChEMBL-Cells; CHEMBL4295467
DR   ChEMBL-Targets; CHEMBL4296487
DR   Cosmic-CLP; 1330993
DR   DepMap; ACH-001383
DR   EGA; EGAS00001000978
DR   GDSC; 1330993
DR   GEO; GSM827268
DR   GEO; GSM1670354
DR   PharmacoDB; PWR1E_1279_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3775
DR   PubChem_Cell_line; CVCL_3775
DR   Wikidata; Q54948720
RX   Patent=US5814452;
RX   PubMed=8761420;
RX   PubMed=8977636;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Group: Patented cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11611.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transformant: Ad12-SV40 hybrid virus.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=2.52%; Native American=0%; East Asian, North=2.82%; East Asian, South=0%; South Asian=0%; European, North=64.08%; European, South=30.58% (PubMed=30894373).
CC   Derived from site: In situ; Prostate, epithelium; UBERON=UBERON_0000428.
CC   Cell type: Epithelial cell of prostate; CL=CL_0002231.
ST   Source(s): ATCC; Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 12,13
ST   D5S818: 11,13
ST   D7S820: 9,11
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 14,16
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   67Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 29
//
RX   Patent=US5814452;
RA   Webber M.M., Rhim J.S.;
RT   "Human prostatic cell lines immortalized by adenovirus 12-simian virus
RT   40 (AD12/SV40) hybrid virus.";
RL   Patent number US5814452, 29-Sep-1998.
//
RX   PubMed=8761420; DOI=10.1093/carcin/17.8.1641;
RA   Webber M.M., Bello D., Kleinman H.K., Wartinger D.D., Williams D.E.,
RA   Rhim J.S.;
RT   "Prostate specific antigen and androgen receptor induction and
RT   characterization of an immortalized adult human prostatic epithelial
RT   cell line.";
RL   Carcinogenesis 17:1641-1646(1996).
//
RX   PubMed=8977636; DOI=10.1002/(SICI)1097-0045(199612)29:6<386::AID-PROS7>3.0.CO;2-6;
RA   Webber M.M., Bello D., Quader S.T.A.;
RT   "Immortalized and tumorigenic adult human prostatic epithelial cell
RT   lines: characteristics and applications. Part I. Cell markers and
RT   immortalized nontumorigenic cell lines.";
RL   Prostate 29:386-394(1996).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//